Literature DB >> 8781410

Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice.

E C LaCasse1, M T Saleh, B Patterson, M D Minden, J Gariépy.   

Abstract

Shiga-like toxin-1 (SLT-1) is a bacterial toxin that kills cells by inhibiting protein synthesis. SLT-1 is composed of one cytotoxic A-subunit and five B-subunits that bind to CD77, a cell-surface glycolipid. In the human hematopoietic system, CD77 expression is restricted to a subset of activated B cells and derived cancers. Here we report that SLT-1 treatment of murine bone marrow ex vivo effectively cures severe combined immunodeficient mice of a human B-cell lymphoma xenograft while sparing normal hematopoietic precursor cells. Flow cytometry results using fluorescein isothiocyanate-labeled SLT-1 B-subunit show the high prevalence of expression of SLT-1 receptors (CD77) in human non-Hodgkin's lymphomas, especially follicular lymphomas. These results suggest the use of SLT-1 for the purging of human bone marrow before autologous bone marrow transplant in the case of CD77+ B-cell lymphomas as just one of many possible uses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum.

Authors:  Maria Teresa Tarragó-Trani; Brian Storrie
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

Review 2.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

Review 3.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

4.  Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.

Authors:  Mohammad Sadraeian; Mohammad Bagher Ghoshoon; Milad Mohkam; Zeinab Karimi; Sara Rasoul-Amini; Younes Ghasemi
Journal:  Virol Sin       Date:  2013-01-17       Impact factor: 4.327

5.  Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells.

Authors:  Maurizio Brigotti; Valentina Arfilli; Domenica Carnicelli; Laura Rocchi; Cinzia Calcabrini; Francesca Ricci; Pasqualepaolo Pagliaro; Pier Luigi Tazzari; Roberta R Alfieri; Pier Giorgio Petronini; Piero Sestili
Journal:  Toxins (Basel)       Date:  2013-02-21       Impact factor: 4.546

Review 6.  Shiga toxin and its use in targeted cancer therapy and imaging.

Authors:  Nikolai Engedal; Tore Skotland; Maria L Torgersen; Kirsten Sandvig
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

7.  Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.

Authors:  Ana Valeria Meléndez; Rubí M-H Velasco Cárdenas; Simon Lagies; Juliane Strietz; Lina Siukstaite; Oliver S Thomas; Jana Tomisch; Wilfried Weber; Bernd Kammerer; Winfried Römer; Susana Minguet
Journal:  Cell Mol Life Sci       Date:  2022-09-12       Impact factor: 9.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.